Literature DB >> 4046046

Protection by verapamil of globally ischemic rat hearts: energy preservation, a partial explanation.

J A Watts, L J Maiorano, P C Maiorano.   

Abstract

The relationship between energy preservation and the recovery of heart function was studied in globally ischemic hearts which were treated with verapamil. Isolated working rat hearts reperfused after 27 min of ischemia recovered 17.9 +/- 5.11% of pre-ischemic contractile function and had markedly reduced tissue ATP, total adenine nucleotide, and creatine phosphate levels. The ATP/ADP ratio was also decreased in these hearts. When verapamil (2 X 10(-6) M) was present before and during ischemia, but not during reperfusion, the recovery of cardiac function following reperfusion was improved (82.4 +/- 12.1%). When hearts were treated with 0.0, 7.5 X 10(-8) M, 5 X 10(-7) M, or 2 X 10(-6) M verapamil, the recovery of cardiac function was proportional to the concentration of verapamil present and showed a linear relationship with the depression of cardiac function prior to ischemia. The ATP, total adenine nucleotide and creatine phosphate levels were significantly higher in those hearts which were treated with verapamil, but the increase was not proportional to the recovery of cardiac function. It is possible that a critical pool of ATP may correlate with the recovery of verapamil treated hearts, but a large degree of mechanical recovery occurred with significant loss of high energy phosphate stores. Thus, while high energy compounds were preserved, there was not a good correlation between recovery of cardiac function and the preservation of total tissue energy reserves. A portion of the protection afforded by verapamil to globally ischemic hearts may be due to energy preservation, but additional mechanisms may also be involved in the enhanced recovery of contractile function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4046046     DOI: 10.1016/s0022-2828(85)80041-9

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

1.  Protection of human, rat, and guinea-pig atrial muscle by mioflazine, lidoflazine, and verapamil against the destructive effects of high concentrations of Ca2+.

Authors:  U Ravens; G S Liu; G Vandeplassche; M Borgers
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

2.  Effects of the calcium antagonist gallopamil on the increase of myocardial extracellular potassium activity during LAD occlusion in dogs.

Authors:  M Budden; M Kirchengast; K M Zhang; W Meesmann
Journal:  Basic Res Cardiol       Date:  1987 May-Jun       Impact factor: 17.165

3.  Comparison of dihydropyridine and phenylalkylamine calcium antagonists in patients with coronary heart disease.

Authors:  G F Rettig; M Jakob; S Sen; A Heisel
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Basic mechanisms involved in the protection of the ischaemic myocardium. The role of calcium antagonists.

Authors:  W G Nayler
Journal:  Drugs       Date:  1991       Impact factor: 9.546

5.  Intracellular calcium and ventricular function. Effects of nisoldipine on global ischemia in the isovolumic, coronary-perfused heart.

Authors:  I Amende; L A Bentivegna; A J Zeind; P Wenzlaff; W Grossman; J P Morgan
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 6.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

7.  Beneficial effects of verapamil during metabolic acidosis in isolated perfused rat hearts.

Authors:  W Markiewicz; S S Wu; R Sievers; W W Parmley; T A Watters; T L James; C B Higgins; J Wikman-Coffelt
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

8.  Effects of verapamil on myocardial stunning in xanthine-oxidase deficient hearts: pre-treatment vs. post-ischemic treatment.

Authors:  T Adachi; T Miura; K Suzuki; O Iimura
Journal:  Basic Res Cardiol       Date:  1994 Jan-Feb       Impact factor: 17.165

9.  Coenzyme Q10 protects ischemic myocardium in an open-chest swine model.

Authors:  D Atar; S A Mortensen; H Flachs; W R Herzog
Journal:  Clin Investig       Date:  1993

10.  A comparison of the cardioprotective effects of calcium antagonists from different classes upon ischaemic damage in the guinea-pig working heart.

Authors:  J G Hugtenburg; M J Mathy; R D Veldsema-Currie; H W Boddeke; J J Beckeringh; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.